Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prevalence of Self-Reported Venous Thromboembolism and Cardiovascular Risk Factors in Patients with Ulcerative Colitis: The GETAID FOCUS Study.
Guillo L, Amiot A, Serrero M, Altwegg R, Roblin X, Atanasiu C, Buisson A, Le Berre C, Reenaers C, Gornet JM, Laharie D, Abitbol V, Biron A, Caron B, Nancey S, Chupin A, Blain A, Vuitton L, Caillo L, Kirchgesner J, Nachury M, Peyrin-Biroulet L; FOCUS Study Group. Guillo L, et al. Among authors: biron a. Dig Dis Sci. 2022 Sep;67(9):4525-4532. doi: 10.1007/s10620-022-07445-4. Epub 2022 Mar 4. Dig Dis Sci. 2022. PMID: 35246801 Free article.
Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study.
Fumery M, Filippi J, Abitbol V, Biron A, Laharie D, Serrero M, Altwegg R, Bouhnik Y, Peyrin-Biroulet L, Gilletta C, Roblin X, Pineton de Chambrun G, Vuitton L, Bourrier A, Nancey S, Gornet JM, Nahon S, Bouguen G, Viennot S, Nachury M, Amiot A. Fumery M, et al. Among authors: biron a. Aliment Pharmacol Ther. 2021 Oct;54(7):944-951. doi: 10.1111/apt.16544. Epub 2021 Jul 23. Aliment Pharmacol Ther. 2021. PMID: 34296456
Comparative Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Non-digestive Malignancy According to Immunomodulator: a Multicentre Cohort Study.
Poullenot F, Amiot A, Nachury M, Viennot S, Altwegg R, Bouhnik Y, Abitbol V, Nancey S, Vuitton L, Peyrin-Biroulet L, Biron A, Fumery M, Picon L, Vidon M, Reenaers C, Serrero M, Savoye G, Beaugerie L, Rivière P, Laharie D. Poullenot F, et al. Among authors: biron a. J Crohns Colitis. 2022 Nov 1;16(10):1523-1530. doi: 10.1093/ecco-jcc/jjac061. J Crohns Colitis. 2022. PMID: 35512337
Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study.
Fumery M, Defrance A, Roblin X, Altwegg R, Caron B, Hébuterne X, Stefanescu C, Meyer A, Nachury M, Laharie D, Nancey S, Le Berre C, Serrero M, Geyl S, Giletta C, Ah-Soune P, Duveau N, Uzzan M, Abitbol V, Biron A, Tran-Minh ML, Paupard T, Vuitton L, Elgharabawy Y, Peyrin-Biroulet L. Fumery M, et al. Among authors: biron a. Aliment Pharmacol Ther. 2023 Feb;57(4):426-434. doi: 10.1111/apt.17358. Epub 2022 Dec 19. Aliment Pharmacol Ther. 2023. PMID: 36534763
Long-term Outcome of Risankizumab in Crohn's Disease: a Real-world GETAID Study.
Fumery M, Caron B, Hébuterne X, Altwegg R, Roblin X, Stefanescu C, Meyer A, Nachury M, Laharie D, Le Berre C, Guillo L, Biron A, Caillo L, Buisson A, Nancey S, Uzzan M, Vuitton L, Gilletta C, Geyl S, Blain A, Kirchgesner J, Ah-Soune P, Duveau N, Vidon M, Abitbol V, Paupard T, Tran-Minh ML, Defrance A, Peyrin-Biroulet L. Fumery M, et al. Among authors: biron a. Clin Gastroenterol Hepatol. 2024 Dec;22(12):2451-2458.e1. doi: 10.1016/j.cgh.2024.04.016. Epub 2024 May 9. Clin Gastroenterol Hepatol. 2024. PMID: 38729389
Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID.
Caron B, Seksik P, Buisson A, Wils P, Savoye G, Stefanescu C, Laharie D, Guillo L, Abitbol V, Bonnet J, Altwegg R, Vuitton L, Moussata D, Bourreille A, Biron A, Gilletta C, Fumery M, Nahon S, Nancey S, Camara H, Peyrin-Biroulet L. Caron B, et al. Among authors: biron a. Therap Adv Gastroenterol. 2024 Aug 7;17:17562848241265776. doi: 10.1177/17562848241265776. eCollection 2024. Therap Adv Gastroenterol. 2024. PMID: 39119370 Free PMC article.
Real-world effectiveness and safety of CT-P13, an infliximab biosimilar, for inflammatory bowel diseases: A prospective national observational cohort study (ReFLECT study).
Laharie D, Bouhnik Y, Vuitton L, Biron A, Pierron G, Brault Y, Assing M, Bouzidi A, Amiot A, Nancey S. Laharie D, et al. Among authors: biron a. Clin Res Hepatol Gastroenterol. 2024 Oct 22;48(10):102483. doi: 10.1016/j.clinre.2024.102483. Online ahead of print. Clin Res Hepatol Gastroenterol. 2024. PMID: 39448029 Free article.
148 results